MPMikhail Vladimirovich Pokrovskii

Mikhail Vladimirovich Pokrovskii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mikhail Vladimirovich Pokrovskii has a total of 318 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Influence of the ATP-sensitive potassium channel blocker glibenclamide on the nephroprotective effect of polydatin in cisplatin-induced acute kidney injury

    by A. S. Netrebenko, M. V. Pokrovsky, D. V. Bessmertniy, А. С. Нетребенко, М. В. Покровский, Д. В. Бессмертный

    Relevance. Acute kidney injury is a serious pathological process that often develops during treatment with cisplatin. The ability of the phytoalexin polydatin to reduce the negative impact of cisplatin on kidney function has previously been demonstrated. However, the mechanisms by which polydatin exerts its nephroprotective potential have not been fully elucidated. Objective. To investigate the effect of the ATP-sensitive potassium channel blocker glibenclamide on the implementation of the nephroprotective effect of polydatin in modeling cisplatin-induced acute kidney injury. Materials and methods. The study was conducted on 50 white laboratory male Wistar rats weighing 250-300g, which were divided into 5 groups (n = 10). Modeling of acute kidney injury was carried out by intraperitoneal administration of cisplatin at a dose of 5 mg/kg on the 1st and 8th days of the experiment. For the purpose of nephroprotection, polydatin was administered intragastrically daily at a dose of 12 mg/kg. To block ATP-sensitive potassium channels, glibenclamide was used intragastrically at a dose of 5 mg/kg 30 minutes before the administration of polydatin. 14 days after the first administration of cisplatin, laboratory and instrumental indicators of renal function were assessed. Results. Adequate functioning of ATP-sensitive potassium channels plays a key role in the nephroprotective properties of polydatin in a model of cisplatin-induced acute kidney injury. Administration of glibenclamide to block ATP-sensitive potassium channels, combined with polydatin, was associated with a significant decrease in the protective potential of the latter: increased azotemia, deterioration of the glomerular filtration rate and fractional sodium excretion, and decreased renal microcirculation. Against the background of a decrease in the microcirculation index, the level of proteinuria also increased. Conclusions. ATP-sensitive potassium channels have a significant influence on the implementation of the nephroprotective potential of polydatin in the modeling of cisplatin-induced acute kidney injury.

  • Open Access

    HAEE tetrapeptide as a promising neuroprotector: comparison with Piracetam in an experimental model of Alzheimer's disease

    by Evgenii A. Patrakhanov, Elеna V. Kuzubova, Nikita S. Zhunusov, Alexandra I. Radchenko, Vladislav Y. Kurdyukov, Anastasia R. Denisova, Alina A. Avramenko, Mikhail V. Pokrovskii

    Introduction: During the experiment, the effectiveness of tetrapeptide HAEE and the comparison drug Piracetam in correcting neurodegenerative disorders in Alzheimer's disease was investigated in a model of transgenic mice. Materials and Methods: transgenic mice of the APPswe/PS1dE9 (APP/PS1) line were used in the study. The animals were injected with HAEE and Piracetam, after which behavioral tests were performed (“Open Field”, “Light‑Dark Chamber”, “Novel Object Recognition”, “Barnes Maze”). Additionally, gene expression was analyzed using real‑time PCR. The histological study included staining of brain sections with Congo red, followed by counting amyloid plaques in the cortex and hippocampus. Results and Discussion: The administration of HAEE and Piracetam led to an improvement in cognitive performance, with both groups demonstrating memory recovery to the level of intact controls. Histological analysis showed an increase in the number of amyloid plaques in the positive control animals and a reduction in the therapeutic groups by an average of 40%. Gene expression analysis showed that HAEE and Piracetam modulate key molecular pathways associated with neuroplasticity, inflammation, and cellular survival. Changes in the expression of the Stat3, mTor, Vegfa, and Casp3 genes have been observed, reflecting the activation of compensatory neuroprotective mechanisms, as well as the relative stabilization of the pro‑inflammatory markers Il‑6 and Tnf‑a. Conclusion: HAEE tetrapeptide at a dosage of 50 mg per 1 kg and Piracetam at a dosage of 200 mg/kg have a comprehensive positive effect on cognitive functions, molecular and morphological parameters in Alzheimer’s disease. The results obtained in the animal model confirm its high potential as a promising neuroprotective agent, comparable to or superior to classical nootropic drugs.

  • Open Access

    Pharmacological correction of endothelial dysfunction using a complex of grape polyphenols

    by Petr R. Lebedev, Tatyana V. Avtina, Vladimir V. Gureev, Mikhail V. Pokrovskii

    Introduction: Endothelial dysfunction is an important component of cardiovascular disease pathogenesis. Natural polyphenols are of interest as potential endothelioprotective agents. The aim of this study was to evaluate the endothelioprotective activity of a grape polyphenol complex in a mouse model of endothelial dysfunction. Materials and Methods: The study was performed on 50 male C57BL/6 mice. Endothelial dysfunction was induced by administration of L-NAME in drinking water (0.5 mg/mL) for 4 weeks. The animals were divided into five groups (n = 10): intact, control(L-NAME), L-NAME + resveratrol, L-NAME + atorvastatin, and L-NAME + grape polyphenol complex. The estimated daily intake per animal was 0.812 mg of resveratrol, 0.052 mg of atorvastatin, and 0.08 mL of the grape polyphenol complex. Systolic and diastolic blood pressure and endothelium-dependent vascular responses were assessed by invasive hemodynamic monitoring. Morphometric analysis of the heart and kidneys was performed. Edn1, Nos3, and Vegfa expression was evaluated by real-time quantitative PCR. Results and Discussion: The grape polyphenol complex reduced systolic and diastolic blood pressure and the endothelial dysfunction coefficient compared with the L-NAME control. It also reduced morphological changes in the heart and kidneys, increased Nos3 expression, and decreased Edn1 and Vegfa expression. The observed changes approached the values of intact animals and indicate restoration of NO-dependent endothelial regulation. Conclusion: Administration of the grape polyphenol complex at 0.08 mL/day for 4 weeks produced an endothelioprotective effect in C57BL/6 mice with L-NAME-induced endothelial dysfunction. Treatment improved endothelium-dependent vascular responses, systemic hemodynamics, tissue morphology, and endothelial-related gene expression.

  • Open Access

    Neurotrophic Factors in Stroke, Traumatic Brain Injury, and Neurodegeneration: A Convergent Pathophysiological and Translational Perspective

    by Olesya V. Shcheblykina, Darya A. Kostina, Mikhail V. Pokrovskii, Mikhail V. Korokin

    Neurotrophic factors (NTFs), including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and vascular endothelial growth factor (VEGF), play a central role in neuronal survival, plasticity, and regeneration. Despite their distinct etiologies and temporal profiles, stroke (both ischemic and hemorrhagic), traumatic brain injury (TBI), and neurodegenerative diseases (NDDs), including Alzheimer’s disease (AD) and Parkinson’s disease (PD), converge on a common pathophysiological phenotype characterized by excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, blood-brain barrier (BBB) disruption, and neuronal apoptosis. Neurotrophic factors modulate these pathological cascades through tropomyosin receptor kinase (Trk) receptors, p75 neurotrophin receptor (p75NTR), and related signaling pathways, thereby supporting neuroprotection, neurogenesis, and synaptogenesis. Experimental evidence from preclinical models demonstrates robust beneficial effects of neurotrophin-based interventions in stroke, TBI, AD, and PD across protein, gene, and cell-based strategies. However, clinical translation remains severely limited. Early-phase clinical trials of adeno-associated virus (AAV)-mediated GDNF and neurturin gene therapy for PD, ex vivo NGF gene therapy for AD, and BDNF gene therapy for AD have confirmed acceptable safety profiles but yielded modest or inconsistent efficacy, largely due to constraints in brain delivery, the need for invasive neurosurgical procedures, restricted target coverage, suboptimal control of expression, and marked patient heterogeneity. Consequently, the principal barrier to clinical success is not biological validity, but the lack of safe, effective and scalable delivery platforms capable of bypassing or functionally modulating the BBB. In this review we synthesize shared pathophysiological mechanisms linking stroke, TBI and NDDs; examine the biology, receptor systems, and signaling pathways of key neurotrophic factors; summarize preclinical evidence for their therapeutic potential; and critically evaluate current delivery strategies, including viral vectors, lipid nanoparticles, exosomes, cell-based therapies, small-molecule mimetics, and intranasal administration. We conclude that overcoming delivery barriers through development of improved viral and non-viral platforms, minimally invasive administration routes, controllable expression systems, and rational patient stratification based on disease stage and biomarkers will be essential to fully realize the neuroprotective and neuroregenerative potential of neurotrophin-based therapies for acute and chronic brain disorders.


  • Open Access

    Morphometric visualization, analysis, and assessment of atherosclerotic lesions in an apolipoprotein E–deficient mouse model (ApoE−/−)

    by Petr R. Lebedev, Natalya V. Syrykh, Mikhail V. Pokrovskii

    Introduction: The improvement of diagnostic methods in atherosclerosis is aimed at accurately determining the stage of the pathological process and eliminating subjective interpretation of data. Implementation of this approach increases the reliability of comparative assessment of the effectiveness of therapeutic and interventional strategies and reduces statistical variability within experimental studies. Materials and Methods: The study was performed on 20 male ApoE−/− mice (40 weeks old) divided into groups receiving a standard diet or a Western diet. After anesthesia, PBS perfusion was performed; the heart with the aorta was excised and fixed in 10% formalin; the aorta was cleaned and stained with Oil Red O. The aorta was longitudinally opened, photographed (GelDoc), and quantitatively analyzed using a Python script. Data are presented as mean ± SD; statistical significance was assessed using Student’s t-test at p < 0.05. Results and Discussion: Thus, the use of the Oil Red O staining method in combination with automated image analysis in Python enables a transition from subjective assessment to precise quantitative measurement of the area of atherosclerotic lesions. This approach increases the reliability of screening therapeutic interventions in experimental models and enhances the statistical power of the study. Conclusion: In this study, an original approach to morphometric visualization, analysis, and quantitative assessment of atherosclerotic lesions of the vascular wall in an apolipoprotein E–deficient mouse model (ApoE−/−) is proposed and validated for the first time.

  • Синтез, прогноз фармакологической активности и ADME-характеристик новых производных 4-(аминометил)-1-бензилпирролидин-2-она как ингибиторов Cdk1 и их токсикологический профиль

    by Вера Александровна Бунятян, Михаил Владимирович Покровский, Дарья Александровна Костина, Наталья Дмитриевна Бунятян

    Разработана оптимизированная схема синтеза 4-(аминометил)-1-бензилпирролидин-2-она (небрацетама), которая успешно использована для получения производных небрацетама с разными заместителями. Структуры соединений подтверждены данными 1H ЯМР-спектроскопии и ВЭЖХ-МС. Методом молекулярного докинга изучено 20 соединений — производных небрацетама на сродство к циклинзависимой киназе Cdk1. ADME-анализ показал соответствие химической структуры соединений-лидеров правилу Липинского, а для двух соединений — высокую степень проницаемости через ГЭБ. Исследование острой токсичности позволило отнести указанные соединения к 4 классу опасности. На модели мышей с тау-протеинопатией соединения с лабораторными шифрами Y02640 и Y02637 продемонстрировали способность статистически достоверно увеличить продолжительность жизни животных.

  • Open Access

    Synthesis and properties of morpholino-substituted 2 H -imidazole N -oxides as potential endothelioprotectors

    by Alexey A. Akulov, Anna A. Nelyubina, Ilya I. Butorin, Vsevolod V. Melekhin, Maria D. Tokhtueva, Mikhail V. Korokin, Mikhail V. Pokrovskii, Mikhail V. Varaksin, Oleg N. Chupakhin

    5-Morpholino-substituted 2H-imidazole 1-oxides have recently proven themselves as perspective molecules to counteract the pathological states associated with endothelial dysfunction. Among this series, an enhanced pharmacological activity has previously been demonstrated by a p-fluorophenyl-substituted derivative, implying the expediency of the scope expansion with regard to the related halogen-containing molecules. Herein, we report the straightforward synthesis of 7 novel morpholino-tethered 2H-imidazole oxides featuring various haloaryl moieties in their structures with the reaction yields ranging from 40 to 87%. The in silico analysis indicated the specific affinity of the obtained compounds to phosphodiesterase 5a (PDE5a), known as a vital enzyme for the cardiovascular system functioning. At the same time, the in vitro assay on the HEK-293 cell line showed generally low toxicity of the compounds under consideration, suggesting their eligibility for the further in vivo studies.

  • Open Access

    Osteoprotective and regenerative effects of the plant polyphenol resveratrol in postmenopausal osteoporosis: an experimental pharmacological study

    by Belgorod State National Research University, Olga A. Shevchenko, Aleksandr A. Dolzhikov, Mikhail V. Pokrovskii, Oleg S. Gudyrev, Irina N. Dolzhikova

    Background: Osteoporosis is one of the major metabolic, age-related skeletal diseases and a ...

  • Open Access

    Local Administration of pCMV-VEGF165 Plasmid Encoding VEGF Stimulates Tissue Regeneration after Cold Injury in Rats

    by O. V. Shcheblykina, D. A. Kostina, V. V. Arkhipov, E. A. Patrakhanov, A. A. Dolzhikov, V. V. Gureev, N. I. Zhernakova, O. A. Osipova, M. V. Pokrovskii

    INTRODUCTION. Frostbite is a common cold injury that is associated with high rates of disability and requires long and difficult treatment. A vascular endothelial growth factor (VEGF)-encoding pCMV-VEGF165 plasmid-based gene therapy product designed for therapeutic angiogenesis may be a promising tool to promote microcirculation recovery and accelerate lesion healing in local cold injury. This hypothesis needs to be tested in an experimental animal study.AIM. This study aimed to evaluate the efficacy of the pCMV-VEGF165 plasmid gene therapy product for the management of cold injury of a limb in rats.MATERIALS AND METHODS. The study included 42 mature female outbred white laboratory rats. A third to fourth-degree local cold injury was experimentally induced on the dorsal surface of the left hind paw by applying a neodymium magnet frozen in liquid nitrogen. The animals received periwound injections of the test product (super-coiled circular double-stranded plasmid deoxyribonucleic acid at a dose of 60 μg) and placebo (water for injections) on days 2 and 7 after frostbite modelling. The authors evaluated the general condition of the animals, the condition of the damaged paw, the wound area, the healing rate, the body mass, and, after planned euthanasia, the mass of the hind paws.RESULTS. Starting from day 7, the rats treated with the test product showed significantly faster tissue regeneration at the site of cold injury than the control animals. The mean wound surface area reduction in the test animals amounted to 47.36% [25.55; 55.45], whereas that in the control animals was 28.95±18.55% (pCONCLUSIONS. The pCMV-VEGF165 plasmid gene therapy product injected in the periwound area at a dose of 60 μg on days 2 and 7 after cold injury simulation in rats reduces damage, accelerates tissue regeneration under the scab, and expedites scarring.

  • Агонист имидазолиновых рецепторов I1 – I2 в коррекции проявлений экспериментальной преэклампсии у мышей с мутацией в гене Agouti

    by Юлия Михайловна Цуверкалова, Людмила Михайловна Даниленко, Михаил Владимирович Покровский, Владимир Владимирович Гуреев, Нина Ивановна Жернакова, Олег Сергеевич Гудырев

    Преэклампсия — опасное осложнение беременности, характеризуется эндотелиальной дисфункцией макро- и микрососудистого русла и артериальной гипертензией, что приводит к неблагоприятным последствиям как для матери, так и для плода. Несмотря на существующие методы лекарственного лечения, поиск новых и более эффективных фармакологических веществ остается актуальной задачей. Субстанция С7070 (агонист имидазолиновых рецепторов 1 и 2 типов, 20 мг/кг внутрижелудочно, с 13 по 19 сут гестации) вызывает снижение уровня систолического артериального давления на 18,4 %, до 117,9 ± 1,64 мм рт. ст. (p < 0,05), и диастолического артериального давления — на 26,3 %, до 72,6 ± 1,75 мм рт. ст. (p < 0,05), при экспериментальной преэклампсии у мышей с мутацией в гене Agouti. Отмечено снижение коэффициента эндотелиальной дисфункции с 4,66 ± 0,07 до 1,3 ± 0,03 (p < 0,05) и уровня C-реактивного белка в 2,4 раза (p < 0,05), по сравнению с животными без использования фармакологической поддержки. Кроме того, субстанция С7070 обладает выраженным метаболическим действием, снижая концентрацию глюкозы в крови с 10,3 ± 0,3 до 7,3 ± 0,28 ммоль/л (p < 0,05), концентрацию общего холестерина и триглицеридов — с 3,7 ± 0,12 до 2,7 ± 0,12 ммоль/л (p < 0,05) и с 2,2 ± 0,12 до 1,3 ± 0,09 ммоль/л (p < 0,05), соответственно.